and I missed out on all the fun, I'll be back in next week. Good to see you still rocking!!!
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Tesla
TSLA
Apple
AAPL
Meta Platforms
META
Microsoft
MSFT
Petroleo Brasileiro SA Petrobras
PBR
US Stock MarketDetailed Quotes
SLRN Acelyrin
- 2.750
- -0.020-0.72%
Close Mar 21 16:00 ET
- 2.800
- +0.050+1.82%
Post 20:01 ET
276.95MMarket Cap-1.10P/E (TTM)
2.840High2.704Low1.39MVolume2.740Open2.770Pre Close3.85MTurnover1.92%Turnover RatioLossP/E (Static)100.71MShares7.30052wk High0.60P/B199.63MFloat Cap1.84552wk Low--Dividend TTM72.59MShs Float29.880Historical High--Div YieldTTM4.91%Amplitude1.845Historical Low2.765Avg Price1Lot Size
Acelyrin Stock Forum
Sign in to post a comment
$Acelyrin (SLRN.US)$ Acelyrin Adopts Poison Pill as Tang Capital Partners Builds Stake
WSJ· 4 mins ago
Acelyrin said its board approved adopting a limited-duration shareholders' rights plan in response to Tang Capital Partners' accumulation of a stake in the company.
The late-stage biopharma said the plan will issue one right for each share of common stock as of the close of business on March 24. The rights will initially trade with its common stock, and will become exercisable...
WSJ· 4 mins ago
Acelyrin said its board approved adopting a limited-duration shareholders' rights plan in response to Tang Capital Partners' accumulation of a stake in the company.
The late-stage biopharma said the plan will issue one right for each share of common stock as of the close of business on March 24. The rights will initially trade with its common stock, and will become exercisable...
2
$Alumis (ALMS.US)$ $Acelyrin (SLRN.US)$
Can This Biopharma Merger's $737M War Chest Transform Immune Disease Treatment?
Can This Biopharma Merger's $737M War Chest Transform Immune Disease Treatment?
1
$Acelyrin (SLRN.US)$
share buyback at $3, shorts only touched this a tiny bit. I think shorts would only touch this once it got over $3.
share buyback at $3, shorts only touched this a tiny bit. I think shorts would only touch this once it got over $3.
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If...
71
23
3
$Alumis (ALMS.US)$ $Acelyrin (SLRN.US)$
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
Thursday, 20th February at 9:00 pm
LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital...
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
Thursday, 20th February at 9:00 pm
LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital...
1
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow...
59
8
4
$Acelyrin (SLRN.US)$
Based on the provided information, Alumis Inc. (ALMS) and ACELYRIN, Inc. (SLRN) have announced a merger agreement. In this all-stock transaction, ACELYRIN stockholders will receive 0.4274 shares of Alumis common stock for each share of ACELYRIN common stock they own. Post-merger, Alumis stockholders will own approximately 55% of the combined company, while ACELYRIN stockholders will own about 45% on a fully diluted basis. 
Estimating the Post-Merger Stock Price of Alu...
Based on the provided information, Alumis Inc. (ALMS) and ACELYRIN, Inc. (SLRN) have announced a merger agreement. In this all-stock transaction, ACELYRIN stockholders will receive 0.4274 shares of Alumis common stock for each share of ACELYRIN common stock they own. Post-merger, Alumis stockholders will own approximately 55% of the combined company, while ACELYRIN stockholders will own about 45% on a fully diluted basis. 
Estimating the Post-Merger Stock Price of Alu...
1
No comment yet
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Jaguar8 : wise move.
Trytosaveabit OP Jaguar8 : Agreed! Anything that looks out for the common shareholder!